Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor

Journal of Pediatric Surgery

Volumn 36, Issue 8, 2001, Pages 1177-1181

  Soffer, Samuel Z ^a   Moore, James T ^a   Kim, Eugene ^a   Huang, Jianzhong ^a   Yokoi, Akiko ^a   Manley, Christina ^a   O'Toole, Kathleen ^a   Stolar, Charles ^a   Middlesworth, William ^a   Yamashiro, Darrell J ^a   Kandel, Jessica J ^a  

^a Columbia University ^*  (United States)

Author keywords

Angiogenesis; Anti VEGF antibody; Topotecan; Vascular endothelial growth factor; Wilms tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; TOPOTECAN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; IMMUNOHISTOCHEMISTRY; NEPHROBLASTOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0034894341     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2001.25747     Document Type: Conference Paper

References (15)

1. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms tumor
2. Tumor resistance to alkylating agents conferred by mechanism operative only in vivo
3. Camptothecins: A review of their development and schedules of administration
4. Topotecan in pediatric patients and progressive solid tumors: A Pediatric Oncology Group phase II study
5. Anti-angiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
6. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor
7. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
8. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
9. Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
10. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents
11. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
12. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia
13. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
14. Highly specific anti-angiogenic therapy is effective in suppressing growth of experimental Wilms tumors
15. Combined effects of angiostatin and ionizing radiation in antitumor therapy